

HEOR Immunology Publications

Walsh JA, **Adejoro O, Chastek B**, Park Y. Treatment patterns of biologics in US patients with ankylosing spondylitis: descriptive analyses from a claims database. *J Comp Eff Res*. 2018;7(4):369-380.

Walsh JA, **Adejoro O, Chastek B**, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. *J Manag Care Spec Pharm*. 2018:1-11.

Silverberg J, Ghorayeb E, Chen Z, Andria M, Kennedy M, Miao R, **Walker V**, et al. A real-world study evaluating Adequacy of Existing Systemic Treatments for Patients with Moderate-to-Severe Atopic Dermatitis (AD-QUEST): 6-month survey data on flares. Paper presented at: International Investigative Dermatology (IID) 2018; 2018 May 16-19; Orlando, FL.

Mao J, Heithoff KA, **Koep E**, Murphy T, Hammerby E. Cost of subcutaneous immunotherapy in a large insured population in the United States. *Curr Med Res Opin*. 2019 Feb;35(2):351-358.

Burton TM, Ye X, **Parker ED, Bancroft T**, Healey J. Burden of illness associated with tenosynovial giant cell tumors. *Clin Ther*. 2018;40(4):593-602.

Wei W, Ghorayeb E, Andria ML, **Walker V**, et al. A real-world study evaluating Adequacy of Existing Systemic Treatments for patients with moderate-to-severe atopic dermatitis (AD-QUEST): baseline treatment patterns and unmet needs assessment. Paper presented at: 76th Annual Meeting of the Society for Investigative Dermatology (SID) 2017; 2017 Apr 26–29; Portland, OR.

Walsh JA, **Adejoro O, Chastek B**, Chun G, Palmer J. Patterns of treatment adherence, persistence and discontinuation of biologic therapy among patients with psoriatic arthritis in the United States: descriptive analyses from an administrative claims database. Paper presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting; 2017 Mar 27-30; Denver, CO.

Walsh JA, **Adejoro O, Chastek B**, Chun G, Palmer J. Therapy modifications among patients with psoriatic arthritis treated with a biologic in the United States — descriptive analyses from an administrative claims database. Paper presented at: Annual European Congress on Rheumatology (EULAR 2017); 2017 Jun 14-17; Madrid, Spain.

Walsh J, **Adejoro O, Chastek B**, Chun G, Palmer J. Patterns of treatment adherence, persistence and discontinuation of biologic therapy among patients with psoriatic arthritis in the United States: descriptive analyses from an administrative claims database. Paper presented at: Annual European Congress on Rheumatology (EULAR 2017); 2017 Jun 14-17; Madrid, Spain.

Mao J, Heithoff K, **Koep E**, Hammerby E, Murphy T. Per-member-per-month (PMPM) cost of subcutaneous immunotherapy in a large insured population in the United States. Paper presented at: AMCP Managed Care & Specialty Pharmacy Annual Meeting; 2017 Mar 27-30; Denver, CO.

Lofland JH, **Johnson PT**, Ingham MP, **Rosemas SC, White JC**, Ellis L. Shared decision-making for biologic treatment of autoimmune disease: influence on adherence, persistence, satisfaction, and health care costs. *Patient Prefer Adherence*. 2017;11:947-958.

Johnson MP, Johnson JC, Engel-Nitz NM, et al. Management of a rare disease population: a model for identifying a patient population with tuberous sclerosis complex. *Manag Care*. 2017;26(8):34-41.

Hammond E, **Trenz H**, Wang X, Tummala R, Desta B, **Halpern R**. Validation of systemic lupus erythematosus (SLE) diagnosis in claims data using electronic health records (EHR). Paper presented at: 33rd ICPE 2017; 2017 Aug 26-30; Montreal, Canada.

Chastek B, Chen CI, Proudfoot C, Shinde S, Kuznik A, Wei W. Treatment persistence and healthcare costs among patients with rheumatoid arthritis changing biologics in the USA. *Adv Ther*. 2017 Nov;34(11):2422-2435.

Chastek B, Chen CI, Kimura T, Fay J, **Korrer S**, Fiore S. Availability of clinical measures for patients with rheumatoid arthritis in integrated delivery networks who receive a biologic or targeted synthetic disease-modifying antirheumatic drug: a real-world analysis of an electronic health records database. Paper presented at: 2017 ACR/AHRP Annual Meeting; 2017 Nov 3-8; San Diego, CA.

Chastek B, Becker LK, Chen CI, Mahajan P, Curtis JR. Outcomes of tumor necrosis factor inhibitor cycling versus switching to a disease-modifying anti-rheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. *J Med Econ*. 2017 May;20(5):464-473.

Allen-Ramey F, **Mao J, Blauer-Peterson C**, Rock M, Nathan R, **Halpern R**. Healthcare costs for allergic rhinitis patients on allergy immunotherapy: a retrospective observational study. *Curr Med Res Opin*. 2017 Nov;33(11):2039-2047.

Hulbert E, Blauer-Peterson C, Johnson J, Chastek B. Quantifying the delay in receiving biologics vs. conventional DMARDs. Paper presented at: ISPOR 21st Annual International Meeting; 2016 May 21-25; Washington, DC.

Gold DT, Cheng L, **Chastek B, White J**, Silverman SL. Zoledronic acid utilization and factors associated with receipt of follow-up infusion: a survey of patients with postmenopausal osteoporosis. Paper presented at: 84th EAS Congress; 2016 May 29–Jun 1; Innsbruck, Austria.

Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. *Adv Ther*. 2016 Apr;33(4):626-642.

Chastek B, Wei W, Chen CI, et al. Treatment patterns and outcomes in patients with rheumatoid arthritis on biologics who switch to new disease-modifying antirheumatic drugs in integrated healthcare delivery networks. Paper presented at: AMCP 2016 Nexus; 2016 Oct 3-6; National Harbor, MD.

Chastek B, Curtis JR, **Becker L**, Mahajan P, Chen CI. Real-world treatment patterns among rheumatoid arthritis patients who switch from a tumor necrosis factor inhibitor to another medication. Paper presented at: EULAR 2016, Annual European Congress of Rheumatology; 2016 Jun 8–11; London, UK.

Chastek B, Cheng L, **White JC**, Spangler L, Mehta D, Barron R. Persistence with osteoporosis therapies in postmenopausal women in a large US national health plan. Paper presented at: ASBMR Annual Meeting; 2016 Sep 16-19; Atlanta, GA.

Chastek B, Chen CI, Wei W, et al. Cost-effectiveness of tumor necrosis factor inhibitor cycling versus switching to a disease modifying antirheumatic drug with a new mechanism of action among patients with rheumatoid arthritis. Paper presented at: AMCP 2016 Nexus; 2016 Oct 3-6; National Harbor, MD.

Zhang M, **Brenneman SK**, Carter CT, et al. Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis. *Patient Prefer Adherence*. 2015;9:777-784.

Lofland JH, **Johnson P, Watkins A, White J**. Shared decision making among patients with autoimmune conditions initiating biologic therapy. Paper presented at: ISPOR 20th Annual International Meeting; 2015 May 16-20; Philadelphia, PA.

Halpern R, Wolbeck R, Blauer-Peterson C, Wu Y, Gandhi SK. Adherence to glatiramer acetate 40 mg versus oral disease-modifying therapies for multiple sclerosis. Paper presented at: ISPOR 18th Annual European Congress; 2015 Nov 7-11; Milan, Italy.

Engel-Nitz NM, Ogale S, Kulakodlu M. Use of anti-tumor necrosis factor therapy: a retrospective study of monotherapy and adherence to combination therapy with non-biologic disease-modifying anti-rheumatic drugs. *Rheumatol Ther*. 2015;2(2):127-139.

Engel-Nitz N, Burke J, Garris C, et al. Distinguishing levels of disease flare in patients with systemic lupus erythematosus using claims data. Paper presented at: AMCP's 2010 Educational Conference; 2010 Oct 13-15; St. Louis, MO.

Curtis JR, **Chastek B, Becker L**, et al. Cost and effectiveness of biologics for rheumatoid arthritis in a commercially insured population. *J Manag Care Spec Pharm*. 2015;21(4):318-329.

Chastek B, Liu F, Shah H, Harrison DJ. Effect of a tier change policy for biologic disease-modifying antirheumatic drugs (DMARDs) on health care cost and medication effectiveness. Paper presented at: ISPOR 20th Annual International Meeting; 2015 May 16-20; Philadelphia, PA.

Chastek B, Harnett J, Curtis JR, et al. Real-world evaluation of patients with rheumatoid arthritis initiating tofacitinib vs adalimumab and etanercept. Paper presented at: 2015 ACR/ARHP Annual Meeting; 2015 Nov 6-11; San Francisco, CA.

Chastek B, Curtis JR, **Becker L**, Joseph GJ, Chen C. Effectiveness of monotherapy in rheumatoid arthritis patients initiating a tumor necrosis factor inhibitor (TNFi) vs a non-TNFi in a large U.S. commercial and Medicare Advantage Plan. Paper presented at: 2015 ACR/ARHP Annual Meeting; 2015 Nov 6-11; San Francisco, CA.

Chastek B, Cheng L, **White J**, Spangler L, Mehta D, Barron R. Persistence with osteoporosis therapies in postmenopausal women in a large US national health plan. Paper presented at: 2015 ACR/ARHP Annual Meeting; 2015 Nov 6-11; San Francisco, CA.

Carter C, Farahi K, **Johnson M**, Olson W, Zhang M. Patient choice of dosing frequency among moderate-to-severe plaque psoriasis patients with adalimumab, etanercept, and/or ustekinumab experience. Paper presented at: 2015 Fall Clinical Dermatology Conference; 2015 Oct 1-4; Las Vegas, NV.

Altan A, Shiozawa A, **Bancroft T**, Singh JA. A real-world study of switching from allopurinol to febuxostat in a health plan database. *J Clin Rheumatol*. 2015 Dec;21(8):411-418.

Allen-Ramey F, **Mao J**, Nathan R, Rock M, **Halpern R**. Allergic rhinitis patient factors associated with allergen immunotherapy treatment persistence. Paper presented at: 2015 AAAI Annual Meeting; 2015 Feb 20-24; Houston, TX.

Thayer SW, Stolshek BS, **Gomez Rey G**, **Seare JG**. Impact of osteoporosis on high-cost chronic diseases. *Value Health*. 2014;17(1):43-50.

Shah N, Bonafede M, **Chastek B**, Thomson E, **Song R**, Harrison DJ. Treatment persistence with combination versus monotherapy in commercially insured patients with rheumatoid arthritis. Paper presented at: ISPOR 19th Annual International Meeting; 2014 May 31-Jun 4; Montreal, Canada.

Johnson JC, **Johnson MP**, **Engel-Nitz NM**, et al. Improving identification of tuberous sclerosis complex: a model of high-risk patient. Paper presented at: 2014 World TSC Conference; 2014 Jul 3-6; Washington, DC.

Johnson JC, **Johnson MP**, **Engel-Nitz NM**, et al. Improving identification of tuberous sclerosis complex: a model of high-risk patient. Paper presented at: American Academy of Pediatrics (AAP) 2014 National Conference and Exhibition; 2014 Oct 11-14; San Diego, CA.

Gold D, Silverman S, **Chastek B**, et al. A patient survey study of zoledronic acid utilization and factors associated with persistence. Paper presented at: 2014 ACR/ARHP Annual Meeting; 2014 Nov 14-19; Boston, MA.

Brenneman SK, Carter C, **Essoi B**, et al. Patient-reported treatment satisfaction in moderate to severe plaque psoriasis. Paper presented at: Fall Clinical Dermatology Conference; 2014 Oct 15-19; Las Vegas, NV.

Brenneman SK, Carter C, **Essoi B**, et al. Patient choice of dosing frequency of biologic treatment of plaque psoriasis. Paper presented at: Fall Clinical Dermatology Conference; 2014 Oct 15-19; Las Vegas, NV.

Brenneman S, Carter C, **Essoi B**, et al. Patient choice on injection frequency of biologic treatment of moderate to severe plaque psoriasis. Paper presented at: Fall Clinical Dermatology Conference; 2014 Oct 15-19; Las Vegas, NV.

Garris C, Jhingran P, Bass D, **Engel-Nitz NM**, **Riedel A**, Dennis G. Healthcare utilization and cost of systemic lupus erythematosus in a US managed care health plan. *J Med Econ*. 2013;16(5):667-77.

Furst DE, Clarke AE, Fernandes AW, **Bancroft T**, Greth W, **Iorga SR**. Incidence and prevalence of adult systemic lupus erythematosus in a large US managed-care population. *LUPUS*. 2013 Jan;22(1):99-105.

Curtis JR, **Chastek B**, **Becker L**, et al. Further evaluation of a claims-based algorithm to determine the effectiveness of biologics for rheumatoid arthritis using commercial claims data. *Arthritis Res Ther*. 2013 Mar 8;15(2):404.

Curtis J, **Chastek B**, **Becker L**, et al. Effectiveness and cost per responder with first-line biologics for rheumatoid arthritis using a validated, claims-based algorithm in a large U.S. commercial health plan. Paper presented at: ISPOR 18th Annual International Meeting; 2013 May 18-23; New Orleans, LA.

Chastek B, Segal S, Bonafede RP, et al. Comparative effectiveness of TNF blockers in rheumatoid arthritis patients. *Am J Pharm Benefits*. 2013;5(Special Issue):SP14-SP22.

Chastek B, Fox KM, Watson C, Kricorian G, Gandra SR. Psoriasis treatment patterns with etanercept and adalimumab in a United States health plan population. *J Dermatolog Treat*. 2013;24(1):25-33.



11000 Optum Circle, Eden Prairie, MN 55344

Optum[®] is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2019 Optum, Inc. All rights reserved. WF1196055 5/19